



Supplementary Material




Supplementary Figure S1 Histogram of participant CYP2C19 metabolizer status




Supplementary Figure S2. Venn diagram showing the participant overlap across the SSRIs under study. Numbers represents participants with non-missing observations on efficacy and treatment response

Prevalence



Supplementary Figure S3. Prevalence of studied side effects from sertraline (blue), escitalopram (orange) and citalopram (red) across metaboliser groups.



Supplementary Figure S4 Power analysis

Curves showing the results of simulations estimating the power to detect associations between antidepressant efficacy and metabolizer status in our study.